Industry news that matters to you.  Learn more

Archives for November 2012

Scanning Innovation Can Improve Personalized Medicine

New combinations of medical imaging technologies hold promise for improved early disease screening, cancer staging, therapeutic assessment, and other aspects of personalized medicine, according to Ge Wang, director of Virginia Tech’s Center for Biomedical Imaging, in a recent paper that appeared in the refereed journal PLoS One.

Researchers Find Evidence that Brain Compensates after Traumatic Injury

Researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have found that a special magnetic resonance imaging (MRI) technique may be able to predict which patients who have experienced concussions will improve. The results, which were presented this week at the annual meeting of the Radiological Society of North America (RSNA), suggest that, in some patients, the brain may change to compensate for the damage caused by the injury.

Study Advances Use of Stem Cells in Personalized Medicine

Johns Hopkins researchers report concrete steps in the use of human stem cells to test how diseased cells respond to drugs. Their success highlights a pathway toward faster, cheaper drug development for some genetic illnesses, as well as the ability to pre-test a therapy’s safety and effectiveness on cultured clones of a patient’s own cells.

Biomarker Approval Volume Down but Novelty Up, Says Amplion Research

“Approval Trends for Biomarker-Based IVD Tests: Realizing the Promise of Personalized Medicine,” a new report published by Amplion Research (Nov. 2012; 21 pages; free download) analyzes annual trends for FDA approvals since 2008 with some interesting findings.

Metabolic Protein Launches Sugar Feast that Nurtures Brain Tumors

Researchers at The University of Texas MD Anderson Cancer Center have tracked down a cancer-promoting protein’s pathway into the cell nucleus and discovered how, once there, it fires up a glucose metabolism pathway on which brain tumors thrive.

They also found a vital spot along the protein’s journey that can be attacked with a type of drug not yet deployed against glioblastoma multiforme, the most common and lethal form of brain cancer. Published online by Nature Cell Biology, the paper further illuminates the importance of pyruvate kinase M2 (PKM2) in cancer development and progression.